Sort
16,300 grants matching “fatty liver disease”
Tissue-specific roles of FXR in CVD and NASH
$415,080Ronald M. Evans · University Of California, San Diego · P01 · FY2024 · HL
Project 2: Cytoplasmic chromatin fragments (CCF) as a driver of liver cancer and target for intervention during aging
$415,067Peter D. Adams · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2022 · AG
S100A9 and S100A8 in Diabetes and Atherosclerosis
$415,000Karin E. Bornfeldt · University Of Washington · R01 · FY2011 · HL
S100A9 and S100A8 in Diabetes and Atherosclerosis
$415,000Karin E. Bornfeldt · University Of Washington · R01 · FY2010 · HL
Functional Analysis of MGAT Enzymes
$415,000Robert V Farese · J. David Gladstone Institutes · R01 · FY2007 · DK
TARGETING THE MITOCHONDRIAL PYRUVATE CARRIER TO TREAT NONALCOHOLIC STEATOHEPATITIS
$414,925Brian N Finck · Washington University · R01 · FY2016 · DK
Role of Fbxo48-mediated AMPK proteostasis in the pathogenesis and treatment of NAFLD
$414,914Michael J. Jurczak · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · DK
The role of the Akt/PKB signaling in insulin action
$414,871Morris J Birnbaum · University Of Pennsylvania · R01 · FY2014 · DK
Role of methylation-dependent pathways in aging and stress
$414,841Amy Karol Walker · Univ Of Massachusetts Med Sch Worcester · R01 · FY2017 · AG
Role of methylation-dependent pathways in aging and stress
$414,841Amy Karol Walker · Univ Of Massachusetts Med Sch Worcester · R01 · FY2019 · AG
Prospective Evaluation of Acute Kidney Injury (PEAK) Cohort
$414,824Alan S Go · Kaiser Foundation Research Institute · U01 · FY2010 · DK
TARGETING THE MITOCHONDRIAL PYRUVATE CARRIER TO TREAT NONALCOHOLIC STEATOHEPATITIS
$414,730Brian N Finck · Washington University · R01 · FY2017 · DK
Microbiome as Therapeutic Target in Alcoholic Hepatitis
$414,673Bernd G. Schnabl · University Of California, San Diego · U01 · FY2014 · AA
Microbiome as Therapeutic Target in Alcoholic Hepatitis
$414,673Bernd G. Schnabl · University Of California, San Diego · U01 · FY2015 · AA
Them1-Mediated Metabolic Regulation and Pathogenic Role in NAFLD
$414,644David E Cohen · Weill Medical Coll Of Cornell Univ · R01 · FY2016 · DK
A New Molecular Mechanism to Bioengineering a Liver
$414,439Eric Lagasse · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · DK
The Metabolic Syndrome in Mexican American Children
$414,388Ravindranath Duggirala · Texas Biomedical Research Institute · R01 · FY2008 · HD
The Musculoskeletal Cost of Organ Repair
$414,221Leonidas G Koniaris · Indiana University Indianapolis · R01 · FY2020 · GM
The Musculoskeletal Cost of Organ Repair
$414,221Leonidas G Koniaris · Indiana University Indianapolis · R01 · FY2021 · GM
Indiana University (IU) Clinical Center for Chronic Pancreatitis Clinical Research Network
$414,014Evan L Fogel · Indiana University Indianapolis · U01 · FY2018 · DK
Project 2: Cytoplasmic chromatin fragments (CCF) as a driver of liver cancer and target for intervention during aging
$413,965Peter D. Adams · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2024 · AG
Signaling-pathway-based preventative strategies for alcoholic liver disease
$413,936Albert J Fornace · Georgetown University · R01 · FY2012 · AA
Regulation of the innate immune response in alcoholic liver disease by autophagy
$413,925Mark J. Czaja · Emory University · R01 · FY2016 · AA
Glyoxalase 1 and its Role in Metabolic Syndrome
$413,842James J Galligan · University Of Arizona · R01 · FY2023 · DK
Genome-Wide SNP Association in Psoriasis
$413,813Anne Mary Bowcock · Imperial College Of Science, Technology And Medicine · R01 · FY2016 · AR